Citation Impact
Citing Papers
A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression
2005 StandoutNobel
T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus
2008
The MYCN Enigma: Significance of MYCN Expression in Neuroblastoma
2006
New Insights into the Role of RNase L in Innate Immunity
2010
Long COVID: major findings, mechanisms and recommendations
2023 Standout
John Snow's legacy: epidemiology without borders
2013 StandoutNobel
Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid
2011
AP-1 function and regulation
1997 Standout
Poor outcome in patients with advanced stage neuroblastoma and coincident opsomyoclonus syndrome
1994
MYC on the Path to Cancer
2012 Standout
Cancer chemoprevention with dietary phytochemicals
2003 Standout
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1
1989
Paraneoplastic Syndromes Involving the Nervous System
2003 Standout
Keap1-dependent Proteasomal Degradation of Transcription Factor Nrf2 Contributes to the Negative Regulation of Antioxidant Response Element-driven Gene Expression
2003 Standout
Cancer Metastasis: Building a Framework
2006 Standout
The ubiquitin-proteasome proteolytic pathway
1994 StandoutNobel
Otto Warburg's contributions to current concepts of cancer metabolism
2011 Standout
Neuroblastoma: biological insights into a clinical enigma
2003 Standout
Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma
1997
The Science of Stroke: Mechanisms in Search of Treatments
2010 Standout
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.
1993 Standout
Stimuli-responsive nanocarriers for drug delivery
2013 Standout
Symptom patterns in long-duration chronic fatigue syndrome
2000
Opsoclonus‐myoclonus‐ataxia syndrome in neuroblastoma: Clinical outcome and antineuronal antibodies—a report from the children's cancer group study
2001
Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: A report from the Pediatric Oncology Group
1997
RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO
2002 StandoutNature
β-catenin is a target for the ubiquitin–proteasome pathway
1997 Standout
Ectopic Expression of Nonliganded Retinoic Acid Receptor β Abrogates AP-1 Activity by Selective Degradation of c-Jun in Cervical Carcinoma Cells
2004 StandoutNobel
The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase
2005 StandoutNobel
Ras Enhances Myc Protein Stability
1999
Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications?
2002 Standout
Human neuroblastoma cell lines that express N-myc without gene amplification
1993
Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy.
1996
Differential interaction of plakoglobin and β-catenin with the ubiquitin-proteasome system
2000 StandoutNobel
Neuroblastoma-associated opsoclonus-myoclonus treated with intravenously administered immune globulin G
1995
2‐5A induces a conformational change in the ankyrin‐repeat domain of RNase L
2005
Amplification of cellular oncogenes: A predictor of clinical outcome in human cancer
1990
Molecular biology and genetics of human neuroblastoma
1989
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes
2002 Standout
Molecular themes in oncogenesis
1991 StandoutNobel
Ubiquitylation and Destruction of Endogenous c-MycS by the Proteasome: Are Myc Boxes Dispensable?
2000 StandoutNobel
Molecular Physiology of Preconditioning-Induced Brain Tolerance to Ischemia
2008
Dimerization, DNA Binding, and Transactivation Properties of Hypoxia-inducible Factor 1
1996 StandoutNobel
Neuroblastoma
2007 Standout
N-myc oncogene and stage iv-s neuroblastoma preliminary observations on ten cases
1990
Opsoclonus‐myoclonus‐ataxia syndrome in neuroblastoma: Histopathologic features–A report from the children's cancer group†
2001
RNase L: Its biological roles and regulation
2006
Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L
2011 StandoutNobel
No Evidence for XMRV Nucleic Acids, Infectious Virus or Anti-XMRV Antibodies in Canadian Patients with Chronic Fatigue Syndrome
2011 StandoutNobel
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study.
1998
Biology and Genetics of Human Neuroblastomas
1997
Modes of regulation of ubiquitin-mediated protein degradation
2000 StandoutNobel
Interferon-inducible antiviral effectors
2008 Standout
Comparative Genomic Hybridization for Molecular Cytogenetic Analysis of Solid Tumors
1992 StandoutScience
Molecular Recognition of Protein−Ligand Complexes: Applications to Drug Design
1997 Standout
Ubiquitin-dependent c-Jun degradation in vivo is mediated by the δ domain
1994
The 26S Proteasome: A Molecular Machine Designed for Controlled Proteolysis
1999 Standout
The cyclosome, a large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis.
1995 StandoutNobel
Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity
2022 StandoutNobel
Increased Frequency of Aberrations in the p53/MDM2/p14ARF Pathway in Neuroblastoma Cell Lines Established at Relapse
2006
c-Myc Proteolysis by the Ubiquitin-Proteasome Pathway: Stabilization of c-Myc in Burkitt's Lymphoma Cells
2000
Hypoxia-inducible factor 1α protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations
2000 StandoutNobel
EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance
2019 StandoutNobel
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
2003
MYCN Expression Is Not Prognostic of Adverse Outcome in Advanced-Stage Neuroblastoma With Nonamplified MYCN
2000
Interferon-Stimulated Genes: A Complex Web of Host Defenses
2014 StandoutNobel
Mechanisms Underlying Ubiquitination
2001 Standout
Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway.
1995 StandoutNobel
A review on cognitive behavorial therapy (CBT) and graded exercise therapy (GET) in myalgic encephalomyelitis (ME) / chronic fatigue syndrome (CFS): CBT/GET is not only ineffective and not evidence-based, but also potentially harmful for many patients with ME/CFS.
2009
Oxidative Stress Sensor Keap1 Functions as an Adaptor for Cul3-Based E3 Ligase To Regulate Proteasomal Degradation of Nrf2
2004 Standout
The ubiquitin-proteasome pathway: on protein death and cell life
1998 StandoutNobel
Molecular Biology of Neuroblastoma
1999
myc gene amplification and expression in primary human neuroblastoma.
1990
Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor–κB and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis
2003
The Ubiquitin-Proteasome Proteolytic Pathway: Destruction for the Sake of Construction
2002 StandoutNobel
Degradation of the Proto-Oncogene Product c-Fos by the Ubiquitin Proteolytic System In Vivo and In Vitro: Identification and Characterization of the Conjugating Enzymes
1995 StandoutNobel
MYCN protein expression as a predictor of neuroblastoma prognosis.
1997
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
2008 Standout
THE UBIQUITIN SYSTEM
1998 StandoutNobel
Combining DNA Damage Induction with BCL-2 Inhibition to Enhance Merkel Cell Carcinoma Cytotoxicity
2020
SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis.
2002
The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop
2011
The ubiquitin conjugation system is required for ligand-induced endocytosis and degradation of the growth hormone receptor.
1996 StandoutNobel
Works of C.v. Herst being referenced
Structural and Functional Features of the 37-kDa 2-5A-Dependent RNase L in Chronic Fatigue Syndrome
2002
Double-stranded RNA-dependent protein kinase (PKR) is a stress-responsive kinase that induces NFκB-mediated resistance against mercury cytotoxicity
2005
Biochemical Evidence for a Novel Low Molecular Weight 2-5A-Dependent RNase L in Chronic Fatigue Syndrome
1997
Single copies of the N-myc oncogene in neuroblastomas from children presenting with the syndrome of opsoclonus-myoclonus
1988
2′,5′-Oligoadenylate size is critical to protect RNase L against proteolytic cleavage in chronic fatigue syndrome
2005
High levels of N-myc protein in a neuroblastoma cell line lacking N-myc amplification.
1991
N-myc amplification in an infant with stage IVS neuroblastoma.
1987
Characterization of a novel myeloma cell line, MM.1.
1989
Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification.
1990
Interactions Between Rnase L Ankyrin-Like Domain and ABC Transporters as a Possible Origin for Pain, Ion Transport, CNS and Immune Disorders of Chronic Fatigue Immune Dysfunction Syndrome
2001
Establishment and characterization of a neuroendocrine skin carcinoma cell line.
1987